Exploring the Impact of CDK 4/6 Inhibitors Through Case-Based Panel Discussion

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this case-based panel discussion on the role of CDK 4/6 inhibitors in clinical practice. 

Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of anticancer medications. It is also helpful in reducing or eliminating endocrine resistance when used in combination with endocrine therapy. It can be used for the treatment of hormone receptor–positive (HR+) breast cancer.

The CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib are observed to enhance the change in the treatment paradigm for patients with HR+/HER2− advanced breast cancer. Moreover, these drugs have demonstrated a meaningful improvement in PFS when used for first- or later-line therapy.

Therefore, listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars